Mark Heffernan

Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia.

Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA.

Stonehaven Incubate AG provides investment services in animal health sector. The company is headquartered in Andermatt, Switzerland.

AniV8, Inc. is an American clinical sensor technology company that aims to improve animal health by applying innovative, high-tech sensor science to targeted disease states. AniV8 has developed the first wearable health monitor for dogs and cats that will diagnose and monitor osteoarthritis (OA) pain using proprietary algorithms to measure the quality of movement. The device has clear points of difference from competitors and is the only wearable to measure the quality, not quantity, of motion. AniV8 has completed an oversubscribed pre-seed funding round and has collaborated with Elanco Animal Health to evaluate its wearable technology in research settings. The company was founded by B Duncan X. Lascelles, who is also the director and chief scientific advisor, and the CEO is Ellie Virtue.